First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Hyun Cheol Chung; Yung Jue Bang; Charles S Fuchs; Shu Kui Qin; Taroh Satoh; Kohei Shitara; Josep Tabernero; Eric Van Cutsem; Maria Alsina; Zhu Alexander Cao; Jia Lu; Pooja Bhagia; Chie Schin Shih; Yelena Y. Janjigian

doi:10.2217/fon-2020-0737

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Hyun Cheol Chung, Yung Jue Bang, Charles S Fuchs, Shu Kui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Maria Alsina, Zhu Alexander Cao, Jia Lu, Pooja Bhagia, Chie Schin Shih, Yelena Y. Janjigian

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

105 Citations (Scopus)

Abstract

Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov.

Original language	English
Pages (from-to)	491-501
Number of pages	11
Journal	Future Oncology
Volume	17
Issue number	5
DOIs	https://doi.org/10.2217/fon-2020-0737
Publication status	Published - 2021 Feb

Bibliographical note

Publisher Copyright:
© 2020 Future Medicine Ltd

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2020-0737

Cite this

Chung, H. C., Bang, Y. J., S Fuchs, C., Qin, S. K., Satoh, T., Shitara, K., Tabernero, J., Cutsem, E. V., Alsina, M., Cao, Z. A., Lu, J., Bhagia, P., Shih, C. S., & Janjigian, Y. Y. (2021). First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncology, 17(5), 491-501. https://doi.org/10.2217/fon-2020-0737

@article{7f3361261d034777a56b1e2e838deafa,

title = "First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811",

abstract = "Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov.",

author = "Chung, {Hyun Cheol} and Bang, {Yung Jue} and {S Fuchs}, Charles and Qin, {Shu Kui} and Taroh Satoh and Kohei Shitara and Josep Tabernero and Cutsem, {Eric Van} and Maria Alsina and Cao, {Zhu Alexander} and Jia Lu and Pooja Bhagia and Shih, {Chie Schin} and Janjigian, {Yelena Y.}",

note = "Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd",

year = "2021",

month = feb,

doi = "10.2217/fon-2020-0737",

language = "English",

volume = "17",

pages = "491--501",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer

T2 - KEYNOTE-811

AU - Chung, Hyun Cheol

AU - Bang, Yung Jue

AU - S Fuchs, Charles

AU - Qin, Shu Kui

AU - Satoh, Taroh

AU - Shitara, Kohei

AU - Tabernero, Josep

AU - Cutsem, Eric Van

AU - Alsina, Maria

AU - Cao, Zhu Alexander

AU - Lu, Jia

AU - Bhagia, Pooja

AU - Shih, Chie Schin

AU - Janjigian, Yelena Y.

PY - 2021/2

Y1 - 2021/2

N2 - Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov.

AB - Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov.

UR - http://www.scopus.com/inward/record.url?scp=85100373371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100373371&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-0737

DO - 10.2217/fon-2020-0737

M3 - Article

C2 - 33167735

AN - SCOPUS:85100373371

SN - 1479-6694

VL - 17

SP - 491

EP - 501

JO - Future Oncology

JF - Future Oncology

IS - 5

ER -

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this